PURPOSE: The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma. PATIENTS AND METHODS: Twenty-four patients with a median age of 10.5 years were enrolled onto this open-label, multicenter, phase II study. The patients were previously treated with surgical resection (17 of 24), radiotherapy (19 of 24) and chemotherapy (18 of 24). Therapy was administered orally three times a day for 5 consecutive days at the dose of 200 mg/m(2)/dx5 for chemotherapy naive patients. In patients heavily pretreated with chemotherapy the starting dose was of 150 mg/m(2)/dx5. RESULTS: A total of 95 cycles were administered. The median progression free-survival (PFS) was 3 months for the entire group while disease stabilization was obtained in 7 patients (29.1%), all with supratentorial tumors. No CR or PR was observed. TMZ treatment showed a limited toxicity. Thrombocytopenia was the most common hematological adverse effect. Our data suggest a marginal activity of TMZ in children with recurrent high-grade glioma.
PURPOSE: The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma. PATIENTS AND METHODS: Twenty-four patients with a median age of 10.5 years were enrolled onto this open-label, multicenter, phase II study. The patients were previously treated with surgical resection (17 of 24), radiotherapy (19 of 24) and chemotherapy (18 of 24). Therapy was administered orally three times a day for 5 consecutive days at the dose of 200 mg/m(2)/dx5 for chemotherapy naive patients. In patients heavily pretreated with chemotherapy the starting dose was of 150 mg/m(2)/dx5. RESULTS: A total of 95 cycles were administered. The median progression free-survival (PFS) was 3 months for the entire group while disease stabilization was obtained in 7 patients (29.1%), all with supratentorial tumors. No CR or PR was observed. TMZ treatment showed a limited toxicity. Thrombocytopenia was the most common hematological adverse effect. Our data suggest a marginal activity of TMZ in children with recurrent high-grade glioma.
Authors: L S Lashford; P Thiesse; A Jouvet; T Jaspan; D Couanet; P D Griffiths; F Doz; J Ironside; K Robson; R Hobson; M Dugan; A D J Pearson; G Vassal; D Frappaz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: C R Freeman; J P Krischer; R A Sanford; M E Cohen; P C Burger; R del Carpio; E C Halperin; L Munoz; H S Friedman; L E Kun Journal: Int J Radiat Oncol Biol Phys Date: 1993-09-30 Impact factor: 7.038
Authors: H S Friedman; R E McLendon; T Kerby; M Dugan; S H Bigner; A J Henry; D M Ashley; J Krischer; S Lovell; K Rasheed; F Marchev; A J Seman; I Cokgor; J Rich; E Stewart; O M Colvin; J M Provenzale; D D Bigner; M M Haglund; A H Friedman; P L Modrich Journal: J Clin Oncol Date: 1998-12 Impact factor: 44.544
Authors: C Marzolini; L A Decosterd; F Shen; M Gander; S Leyvraz; J Bauer; T Buclin; J Biollaz; F Lejeune Journal: Cancer Chemother Pharmacol Date: 1998 Impact factor: 3.333
Authors: E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton Journal: Br J Cancer Date: 1992-02 Impact factor: 7.640
Authors: E J Estlin; L Lashford; S Ablett; L Price; R Gowing; A Gholkar; J Kohler; I J Lewis; B Morland; C R Pinkerton; M C Stevens; M Mott; R Stevens; D R Newell; D Walker; C Dicks-Mireaux; H McDowell; P Reidenberg; P Statkevich; A Marco; V Batra; M Dugan; A D Pearson Journal: Br J Cancer Date: 1998-09 Impact factor: 7.640
Authors: Zachary Miklja; Viveka Nand Yadav; Rodrigo T Cartaxo; Ruby Siada; Chase C Thomas; Jessica R Cummings; Brendan Mullan; Stefanie Stallard; Alyssa Paul; Amy K Bruzek; Kyle Wierzbicki; Tao Yang; Taylor Garcia; Ian Wolfe; Marcia Leonard; Patricia L Robertson; Hugh Jl Garton; Daniel R Wahl; Hemant Parmar; Jann N Sarkaria; Cassie Kline; Sabine Mueller; Theodore Nicolaides; Chana Glasser; Sarah Es Leary; Sriram Venneti; Chandan Kumar-Sinha; Arul M Chinnaiyan; Rajen Mody; Manjunath P Pai; Timothy N Phoenix; Bernard L Marini; Carl Koschmann Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Jonathan L Finlay; Girish Dhall; James M Boyett; Ira J Dunkel; Sharon L Gardner; Stewart Goldman; Allan J Yates; Marc K Rosenblum; Philip Stanley; Robert A Zimmerman; Dana Wallace; Ian F Pollack; Roger J Packer Journal: Pediatr Blood Cancer Date: 2008-12 Impact factor: 3.167
Authors: Alberto Broniscer; Suzanne J Baker; Clinton F Stewart; Thomas E Merchant; Fred H Laningham; Paula Schaiquevich; Mehmet Kocak; E Brannon Morris; Raelene Endersby; David W Ellison; Amar Gajjar Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531
Authors: Darren Hargrave; Birgit Geoerger; Didier Frappaz; Torsten Pietsch; Lyle Gesner; Laura Cisar; Aurora Breazna; Andrew Dorman; Ofelia Cruz-Martinez; Jose Luis Fuster; Xavier Rialland; Céline Icher; Pierre Leblond; David Ashley; Giorgio Perilongo; Martin Elliott; Martin English; Niels Clausen; Jacques Grill Journal: J Neurooncol Date: 2013-03-04 Impact factor: 4.130